Inside the study for a remedy to fight Congo's deadliest Ebola outbreak
The drug is targeted at Bundibugyo virus, which is responsible for the fast-moving outbreak and is without an approved vaccine or treatment. The trial began in July and is one of several studies launched to find some protection and another way of at least slowing the outbreak.
The Democratic Republic of Congo is experiencing its deadliest Ebola outbreak, with over 8,300 confirmed cases and 4,000 deaths reported since mid-May, according to Medical Xpress and Euronews. The outbreak has spread to seven provinces and is considered the fastest-growing in history.
A trial for a drug to combat the Bundibugyo virus, which is responsible for the outbreak, began in July, with over 250 participants enrolled, Medical Xpress and Winnipeg Free Press reported. The trial is testing Gilead's experimental antiviral pill, obeldesivir.
France has pledged to increase its support for efforts to control the outbreak, with Foreign Minister Jean-Noël Barrot visiting the affected region, RFI English reported.
Brief written by urgent.news from PBS NewsHour, RFI English, Medical Xpress, Winnipeg Free Press, Euronews — 5 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
